Hemophilia B
Drug research and approvals for hemophilia B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 31 studies of hemophilia B are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 17 approved and 12 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 31
- Trials authorized in Canada: 26
- FDA orphan approvals: 17
- EU medicines: 7
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B…NCT07923981 · Phase 3 · Pfizer · starts Oct 23, 2026
- Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome AnalysisNCT07867821 · Not applicable · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Oct 24, 2021
- A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNCT07859527 · Not reported · Pfizer · starts Nov 16, 2026
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and…NCT07644832 · Phase 1 / Phase 2 · Shanghai RAAS Blood Products Co., Ltd. · starts May 31, 2024
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or BNCT07545395 · Phase 3 · Suzhou Alphamab Co., Ltd. · starts Mar 13, 2026
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12…NCT07285460 · Phase 3 · Sanofi · starts Dec 18, 2025
- Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or…NCT07080905 · Phase 3 · CSL Behring · starts Jul 28, 2025
- ATHNdataset RegistryNCT06820515 · Not reported · American Thrombosis and Hemostasis Network · starts Oct 25, 2024
- Synovial Proliferation on Routine Ultrasound: Active or Inactive?NCT06809972 · Not reported · Van Creveldkliniek · starts Jun 1, 2025
Approved 10
- Coagulation factor ix recombinant humanCoagulation factor IX exogenous protein
- Eptacog alfa (activated)Coagulation factor VII exogenous protein
- Nonacog beta pegolCoagulation factor IX exogenous protein
- MarstacimabTissue factor pathway inhibitor inhibitor
- Fidanacogene elaparvovecCoagulation factor IX exogenous gene
- Eftrenonacog alfaCoagulation factor IX exogenous protein
- Coagulation factor ix humanCoagulation factor IX exogenous protein
- Etranacogene dezaparvovecCoagulation factor IX exogenous protein
- Albutrepenonacog alfaCoagulation factor IX exogenous protein
- Eptacog beta (activated)Coagulation factor VII exogenous protein
Phase 3 4
- FitusiranAntithrombin mRNA RNAi inhibitor
- Trenonacog alfaCoagulation factor IX exogenous protein
- ConcizumabTissue factor pathway inhibitor inhibitor
- Anti-inhibitor coagulant complex
Phase 2 3
- BAY-1093884Tissue factor pathway inhibitor inhibitor
- Ataluren80S Ribosome modulator
- Vatreptacog alfa (activated)
Phase 1 or earlier 2
- Verbrinacogene setparvovec
- Eptacog alfa pegol (activated)Coagulation factor VII exogenous protein
How its trials ended
258 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 66 whose ending is known, 62% met their primary endpoint, 0% missed it and 38% stopped early.
- Completed, result not reported11745%
- Ongoing5923%
- Met its primary endpoint4116%
- Status unknown166%
- Stopped: other or unclear125%
- Stopped: sponsor or business decision104%
- Stopped: enrollment or feasibility31%
| Aug 20, 2025 | An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…Fitusiran (SAR439774) | Sanofi-Aventis Canada Inc | Ongoing |
| May 9, 2025 | A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR604 in healthy…SR604 | Equilibra Bioscience LLC | Closed |
| Aug 22, 2024 | A phase 1/2 dose escalation and expansion study of BE-101 for the treatment of adults with moderately severe or severe hemophilia BBE-101 | Be Biopharma | Pending |
| Jun 21, 2024 | A two-part open-label study of REGV131-LNP1265, a crispr/CAS9-based coagulation factor ix gene insertion therapy in participants with hemophilia BREGV131-LNP1265 | Regeneron | Ongoing |
| Aug 16, 2023 | Phase 3b, open-label, multicenter, single-dose study investigating efficacy and safety of CSL222 (etranacogene dezaparvovec) gene therapy administered to adult…CSL222 (etranacogene dezaparvovec) | CSL | Ongoing |
| Mar 15, 2023 | A global, open-label study to investimite the efficacy and safety of serpinpc in subjects with hemophilia B with inhibitorsSerpinpc | Apcintex Limited | Pending |
| Mar 9, 2023 | A global, open-label, adaptive design study to investigate the efficacy and safety of serpinpc in subjects with severe hemophilia A or moderately severe to…Serpinpc | Apcintex Limited | Ongoing |
| Oct 31, 2022 | A phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male…Fitusiran (SAR439774) | Sanofi-Aventis Canada Inc | Ongoing |
| Aug 30, 2022 | An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of marstacimab prophylaxis in severe (coagulation factor activity…Marstacimab (PF-06741086) | Pfizer | Ongoing |
| Dec 21, 2021 | Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or b with or…Concizumab | Novo Nordisk | Ongoing |
| Jun 5, 2026 | HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with… | Pfizer Inc. | Approved |
| Jul 31, 2025 | AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Mar 28, 2025 | QfitliaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with… | Genzyme Corporation | Approved |
| Dec 20, 2024 | AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Oct 11, 2024 | HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Pfizer Inc. | Approved |
| Apr 25, 2024 | BeqvezTreatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis… | Pfizer Inc. | Approved |
| Nov 22, 2022 | HemgenixTreatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current… | CSL Behring LLC | Approved |
| Jul 29, 2022 | RebinynRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency) | Novo Nordisk, Inc. | Approved |
| Oct 5, 2021 | BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency… | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Approved |
| Jun 26, 2020 | BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor… | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Approved |
| Mar 4, 2016 | IdelvionIndicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of… | CSL Behring, LLC | Approved |
| Sep 12, 2014 | RixubisAdults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Mar 28, 2014 | AlprolixAdults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to… | Bioverativ Therapeutics, Inc. | Approved |
| Jun 26, 2013 | RixubisAdults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Feb 11, 1997 | BeneFixFor the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas… | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Approved |
| Feb 20, 2023 | HemgenixEtranacogene dezaparvovec · orphan | CSL Behring GmbH | EMA ↗ |
| Jun 2, 2017 | RefixiaNonacog beta pegol | Novo Nordisk A/S | EMA ↗ |
| May 12, 2016 | AlprolixEftrenonacog alfa · orphan | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| May 11, 2016 | IdelvionAlbutrepenonacog alfa · orphan | CSL Behring GmbH | EMA ↗ |
| Dec 19, 2014 | RixubisNonacog gamma | Baxalta Innovations GmbH | EMA ↗ |
| Aug 27, 1997 | BeneFIXNonacog alfa | Pfizer Europe MA EEIG | EMA ↗ |
| Feb 23, 1996 | NovoSevenEptacog alfa (activated) | Novo Nordisk A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA